drugset / Trial / NCT04278040

Inhalations of Ultra-low Doses of Melphalan for the Treatment of Non-cystic Fibrosis Bronchiectasis

NCT04278040 ↗

NaSingle-groupOpen-labelTreatment

Summary

This non-randomised open-label prospective pilot study evaluates the safety and efficacy of inhalations of ultra-low doses of alkylating drug melphalan for the treatment of non-cystic fibrosis bronchiectasis. All patients will receive 0,1 mg of melphalan in 5 daily inhalations 1 time per day.

Timeline

Start
2018-06-20
Primary completion
2021-12-01
Completion
2021-12-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Melphalan Small molecule 0.1 mg Inhaled

Indications